BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 16356485)

  • 1. Metabolism and transporter-mediated drug-drug interactions of the endothelin-A receptor antagonist CI-1034.
    Sahi J; Sinz MW; Campbell S; Mireles R; Zheng X; Rose KA; Raeissi S; Hashim MF; Ye Y; de Morais SM; Black C; Tugnait M; Keller LH
    Chem Biol Interact; 2006 Feb; 159(2):156-68. PubMed ID: 16356485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81.
    Zhang JG; Dehal SS; Ho T; Johnson J; Chandler C; Blanchard AP; Clark RJ; Crespi CL; Stresser DM; Wong J
    Drug Metab Dispos; 2006 May; 34(5):734-7. PubMed ID: 16501008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil.
    Robertson P; DeCory HH; Madan A; Parkinson A
    Drug Metab Dispos; 2000 Jun; 28(6):664-71. PubMed ID: 10820139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of immortalized Fa2N-4 cells and human hepatocytes as in vitro models for cytochrome P450 induction.
    Hariparsad N; Carr BA; Evers R; Chu X
    Drug Metab Dispos; 2008 Jun; 36(6):1046-55. PubMed ID: 18332078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics.
    Zhou D; Andersson TB; Grimm SW
    Drug Metab Dispos; 2011 Apr; 39(4):703-10. PubMed ID: 21177984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes.
    McGinnity DF; Berry AJ; Kenny JR; Grime K; Riley RJ
    Drug Metab Dispos; 2006 Aug; 34(8):1291-300. PubMed ID: 16679385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro evaluation of the interaction potential of irosustat with drug-metabolizing enzymes.
    Ventura V; Solà J; Peraire C; Brée F; Obach R
    Drug Metab Dispos; 2012 Jul; 40(7):1268-78. PubMed ID: 22451700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective β3-adrenoceptor agonist.
    Takusagawa S; Miyashita A; Iwatsubo T; Usui T
    Xenobiotica; 2012 Dec; 42(12):1187-96. PubMed ID: 22834478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A.
    Shitara Y; Itoh T; Sato H; Li AP; Sugiyama Y
    J Pharmacol Exp Ther; 2003 Feb; 304(2):610-6. PubMed ID: 12538813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of hepatic organic anion-transporting polypeptide by RNA interference in sandwich-cultured human hepatocytes: an in vitro model to assess transporter-mediated drug-drug interactions.
    Liao M; Raczynski AR; Chen M; Chuang BC; Zhu Q; Shipman R; Morrison J; Lee D; Lee FW; Balani SK; Xia CQ
    Drug Metab Dispos; 2010 Sep; 38(9):1612-22. PubMed ID: 20516252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An in vitro evaluation of the victim and perpetrator potential of the anticancer agent laromustine (VNP40101M), based on reaction phenotyping and inhibition and induction of cytochrome P450 enzymes.
    Nassar AE; King I; Paris BL; Haupt L; Ndikum-Moffor F; Campbell R; Usuki E; Skibbe J; Brobst D; Ogilvie BW; Parkinson A
    Drug Metab Dispos; 2009 Sep; 37(9):1922-30. PubMed ID: 19520774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters.
    Chu X; Cai X; Cui D; Tang C; Ghosal A; Chan G; Green MD; Kuo Y; Liang Y; Maciolek CM; Palamanda J; Evers R; Prueksaritanont T
    Drug Metab Dispos; 2013 Mar; 41(3):668-81. PubMed ID: 23293300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: characterizing the importance of transporter-enzyme interplay.
    Lam JL; Okochi H; Huang Y; Benet LZ
    Drug Metab Dispos; 2006 Aug; 34(8):1336-44. PubMed ID: 16698890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro studies investigating the interactions between degarelix, a decapeptide gonadotropin-releasing hormone blocker, and cytochrome P450.
    Sonesson A; Rasmussen BB
    Basic Clin Pharmacol Toxicol; 2011 Sep; 109(3):195-202. PubMed ID: 21496210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of drug-drug interaction potential of bortezomib in vivo in female Sprague-Dawley rats and in vitro in human liver microsomes.
    Lu C; Gallegos R; Li P; Xia CQ; Pusalkar S; Uttamsingh V; Nix D; Miwa GT; Gan LS
    Drug Metab Dispos; 2006 Apr; 34(4):702-8. PubMed ID: 16443666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro assessment of cytochrome P450 inhibition and induction potential of felotaxel (SHR110008).
    Ding Y; Jia Y; Lu C; Liu W; Yang J; Song Y; Zhu Y; Yang L; Ding L; Wen A
    Biomed Pharmacother; 2012 Jun; 66(4):318-21. PubMed ID: 22397757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes.
    Lam JL; Benet LZ
    Drug Metab Dispos; 2004 Nov; 32(11):1311-6. PubMed ID: 15483198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of mRNA expression to detect the induction of drug metabolising enzymes in rat and human hepatocytes.
    Richert L; Tuschl G; Abadie C; Blanchard N; Pekthong D; Mantion G; Weber JC; Mueller SO
    Toxicol Appl Pharmacol; 2009 Feb; 235(1):86-96. PubMed ID: 19118567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro assessment of cytochrome P450 inhibition and induction potential of tanespimycin and its major metabolite, 17-amino-17-demethoxygeldanamycin.
    Gan J; Liu-Kreyche P; Humphreys WG
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):51-6. PubMed ID: 21594721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro hepatotoxicity and cytochrome P450 induction and inhibition characteristics of carnosic acid, a dietary supplement with antiadipogenic properties.
    Dickmann LJ; VandenBrink BM; Lin YS
    Drug Metab Dispos; 2012 Jul; 40(7):1263-7. PubMed ID: 22531045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.